[go: up one dir, main page]

WO2024229245A9 - Génération et classement de fragments d'anticorps fab à haut débit - Google Patents

Génération et classement de fragments d'anticorps fab à haut débit Download PDF

Info

Publication number
WO2024229245A9
WO2024229245A9 PCT/US2024/027448 US2024027448W WO2024229245A9 WO 2024229245 A9 WO2024229245 A9 WO 2024229245A9 US 2024027448 W US2024027448 W US 2024027448W WO 2024229245 A9 WO2024229245 A9 WO 2024229245A9
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
pool
antibodies
antibody fragments
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/027448
Other languages
English (en)
Other versions
WO2024229245A3 (fr
WO2024229245A2 (fr
Inventor
Daria SIZOVA
Yazen JMEIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of WO2024229245A2 publication Critical patent/WO2024229245A2/fr
Publication of WO2024229245A9 publication Critical patent/WO2024229245A9/fr
Publication of WO2024229245A3 publication Critical patent/WO2024229245A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • Monoclonal antibodies are produced by fusing antibody-secreting spleen cells from immunized mice with immortalized myeloma cell to create monoclonal hybridoma cell lines that express the specific antibody in cell culture supernatant.
  • a screening step to identify antibodies that have preferred binding properties is required. This is an expensive and time- consuming step in antibody production.
  • the need for a rapid and efficient screen for antibodies with desirable binding characteristics comes primarily from the fact that antibody binding properties define how a particular antibody functions as a therapeutic agent. Effective blocking antibody therapeutics, for example, usually require the highest possible binding affinity of a given antibody to its target.
  • a method for high-throughput ranking of antibodies by antigen binding can comprise: (a) treating a pool of antibodies to generate a pool of antibody fragments; (b) purifying the pool of antibody fragments; and (c) using a high-throughput antigen binding assay to rank the antibody fragments in the pool of purified antibody fragment according to their binding affinities.
  • the pool of antibody fragments can be generated by treating the pool of antibody fragments with a protease or chemical process, whereby the antibody fragments in the pool of antibody fragments are able to bind antigen with reduced or no avidity effects on antigen binding.
  • the pool of antibody fragments can be a pool of Fab fragments.
  • the pool of Fab fragments can be generated by digesting the pool of antibody fragments with papain.
  • the method can further comprise determining the extent of antibody treatment by SDS-PAGE. Alexion Reference: 0693WO [0007]
  • the method can further comprise determining the extent of antibody treatment by size exclusion chromatography (SEC).
  • SEC size exclusion chromatography
  • the method can further comprise determining the purity of the pool of antibody fragments by SDS-PAGE.
  • the method can further comprise determining the purity of the pool of antibody fragments by size exclusion chromatography (SEC).
  • the pool of antibodies can comprise 2 to 24 different antibodies, 5 to 24 different antibodies, 10-24 different antibodies, 15 to 24 different antibodies, 20 to 24 different antibodies, 24 different antibodies or more than 24 different antibodies.
  • the high-throughput antigen binding assay comprises label-free biosensing.
  • the label-free biosensing can be selected from the group consisting of: ellipsometry; surface plasmon resonance (SPR); localized surface plasmon resonance using noble metal nanoparticles in solution or on a transparent surface; surface acoustic wave (SAW) devices; quartz-crystal microbalance with dissipation (QCM-D); atomic force microscopy; plasmon- photon coupling; transmission sensing through sub-wavelength nanoholes (enhanced optical transmission); photonic crystal sensing; refraction sensing; guided mode resonance sensing; ring resonator sensing; isothermal titration calorimetry (ITC); microscale thermophoresis; and biolayer interferometry (BLI).
  • SPR surface plasmon resonance
  • SAW surface acoustic wave
  • QCM-D quartz-crystal microbalance with dissipation
  • atomic force microscopy plasmon- photon coupling
  • the high-throughput antigen binding assay comprises biolayer interferometry (BLI).
  • BLI biolayer interferometry
  • steps (a) and (b) are performed on a plate.
  • steps (a) through (c) are automated.
  • BRIEF DESCRIPTION OF THE DRAWINGS [0015]
  • FIG.2 depicts size exclusion chromatography (SEC) results for 24 Fab fragments generated by the methods described herein. All 24 Fab fragment were confirmed to be successfully purified. Alexion Reference: 0693WO [0018]
  • FIG.3 depicts 24 Fab fragments generated by the methods described herein and analysed by Biolayer Interferometry (BLI). As shown, variants #1, #5, #6 and #24 did not bind antigen as Fabs, and were eliminated from consideration. The remaining variants were ranked by K off .
  • FIG.4 depicts the BLI ranking results of the 24 Fab fragments. The methods described herein successfully ranked 24 antibodies as Fab fragments by K off .
  • Antibodies are glycoproteins having the same structural characteristics. While Abs exhibit binding specificity to a specific antigen, immunoglobulins include both Abs and other Ab-like molecules that lack antigen specificity.
  • antibody specifically includes monoclonal antibodies, including antibody fragment clones.
  • “Native antibodies and immunoglobulins” are usually heterotetrameric glycoproteins of about 150,000 Daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different Ig isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains.
  • VH variable domain
  • Each light chain has a variable domain at one end (VL) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the Alexion Reference: 0693WO light chain variable domain is aligned with the variable domain of the heavy chain.
  • Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains.
  • native antibodies and immunoglobulins that are not heterotetrameric, e.g., camelid, e.g., llama or alpaca, antibodies, which comprise only a heavy chain (these are single chain immunoglobulins and are sometimes referred to as “VHH” antibodies).
  • variable in the context of antibody variable domains, refers broadly to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. Variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs; i.e., CDR1, CDR2 and CDR3) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework (FR).
  • CDRs complementarity-determining regions
  • FR framework
  • variable domains of native heavy and light chains each comprise four FR regions, largely adopting a ⁇ -sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the ⁇ -sheet structure.
  • the CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies.
  • the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.
  • Antibody fragment refers to any antibody fragment such as Fab, Fab′, F(ab′)2, Fv, and Fd fragments; diabodies; single-chain antibody molecules, including single-domain antibody molecules (dAb) and single-chain Fv molecules (scFv); multispecific antibodies formed from antibody fragments; or other compositions that retain antigen-binding function.
  • Antibody fragments comprise a portion of an intact antibody, generally the antigen binding or variable region of the intact antibody.
  • Antibody fragments may be derived from human or other mammalian cell lines, including natural or genetically modified forms such as humanized, human, chimeric, synthetic, recombinant, hybrid, mutated, grafted, and in vitro generated, from sources including but not limited to bacterial cell lines, insect cell lines, plant cell lines, yeast cell lines, or cell lines of other origin.
  • Antibody fragments may also be derived by controlled lysis of purified antibody with enzymes such as, but not limited to ficin, papain or pepsin. Papain digestion of antibodies produces two identical antigen-binding fragments called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment, whose name reflects its ability to crystallize readily.
  • Fv is the minimum antibody fragment that contains a complete antigen-recognition and binding site. In a two-chain Fv species, this region consists of a dimer of one heavy and one light chain variable domain in tight, non-covalent association.
  • one heavy and one light chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a “dimeric” structure analogous to that in a two- chain Fv species. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
  • VHH exhibits monovalent antigen-binding with only three CDRs.
  • Antibody fragments that are derived from VHH molecules can be fused, with or without a suitable linker peptide, to other VHH fragments to, for example, increase binding through avidity, or to create bi-specific or multi-specific fusion proteins comprising VHH fragments that bind to or more antigens.
  • the Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain.
  • Fab′ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain, including one or more cysteines from the antibody hinge region.
  • Fab′-SH is the designation herein for Fab′ in which the cysteine residue(s) of the constant domains bear a free thiol group.
  • F(ab′)2 antibody fragments originally were produced as pairs of Fab′ fragments that have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
  • the “light chains” of Abs from any vertebrate species can be assigned to one of two clearly distinct types, called kappa ( ⁇ ) and lambda ( ⁇ ), based on the amino acid sequences of their constant domains.
  • immunoglobulins can be assigned to different classes.
  • immunoglobulins There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2.
  • the heavy-chain constant domains that correspond to the different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
  • “Monoclonal antibody,” as used herein, refers broadly to an antibody obtained from a population of substantially homogeneous antibodies, e.g., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that can be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by hybridoma culture methods, uncontaminated by other immunoglobulins.
  • the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies described herein can be made by a hybridoma method or by recombinant DNA methods.
  • the term “monoclonal antibodies” also includes clones of antigen-recognition and binding-site containing antibody fragments (Fv clones) isolated from phage antibody libraries.
  • the monoclonal antibodies herein specifically include “chimeric” antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
  • a “human antibody” also called a “fully human antibody” is an antibody that includes human framework regions and the CDRs from a human immunoglobulin.
  • the framework and the CDRs are from the same originating human heavy and/or light chain amino acid sequence. Framework regions from one human antibody can be engineered to include CDRs from a different human antibody.
  • “Humanized” forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′)2 or other antigen-binding subsequences of antibodies), that contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a CDR of the recipient are replaced by residues from a CDR of a non-human species (such as mouse, camelid, rat or rabbit) or a synthetic sequence (donor antibody), having the desired specificity, affinity and capacity.
  • a non-human species such as mouse, camelid, rat or rabbit
  • donor antibody a synthetic sequence
  • Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • Humanized antibodies can also comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance.
  • all CDRs can be from the donor immunoglobulin in a humanized immunoglobulin.
  • Constant regions need not be present, but if they are, they should be substantially identical to human immunoglobulin constant regions, e.g., at least about 85-90%, such as about 95% or more identical. All parts of a humanized immunoglobulin, except possibly the CDRs, are therefore substantially identical to corresponding parts of natural human immunoglobulin sequences.
  • a “humanized antibody” is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. A humanized antibody binds to the same antigen as the donor antibody that provides the CDRs.
  • the acceptor framework of a humanized immunoglobulin or antibody may have a limited number of substitutions by amino acids taken from the donor framework.
  • Humanized or other monoclonal antibodies can have additional conservative amino acid substitutions that have substantially no effect on antigen binding or other immunoglobulin functions.
  • Humanized immunoglobulins can be constructed by means of genetic engineering.
  • Single-chain Fv or “scFv” antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain.
  • the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding.
  • “Diabodies,” as used herein, refers broadly to small antibody fragments with two antigen-binding sites.
  • Such fragments can comprise, for example, a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH-VL).
  • VH heavy-chain variable domain
  • VL light-chain variable domain
  • VH-VL polypeptide chain
  • the antibody can be purified, for example, (1) to greater than 95% by weight of antibody as determined by the Lowry method (or optimally, to more than 99% by weight), (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing Alexion Reference: 0693WO conditions using Coomassie blue or, preferably, silver stain.
  • Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody’s natural environment will not be present. An isolated antibody is prepared by at least one purification step.
  • Variant refers broadly to a polypeptide that possesses a similar or identical function as an antibody or antibody fragment thereof, but does not necessarily comprise a similar or identical amino acid sequence of the antibody or antibody fragment thereof, or possess a similar or identical structure of an antibody or antibody fragment thereof.
  • a variant having a similar amino acid identity refers to a polypeptide that satisfies at least one of the following: (a) a polypeptide comprising, or alternatively consisting of, an amino acid sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the amino acid sequence of an antibody, including a VHH, or antibody fragment thereof (including a VH domain, VHCDR, VL domain, or VLCDR having an amino acid sequence of any one of those described herein); (b) a polypeptide encoded by a nucleotide sequence, the complementary sequence of which hybridizes under stringent conditions to a nucleotide sequence encoding an a antibody or antibody fragment thereof (including a VH domain, VHCDR, VL domain, or VLCDR having an amino acid sequence of
  • a polypeptide with similar structure to an antibody or antibody fragment thereof, described herein refers to a polypeptide that has a similar secondary, tertiary or quaternary structure of an antibody, or antibody fragment thereof, described herein.
  • the structure of a polypeptide can be determined by methods known to those skilled in the art, including but not limited to, X-ray crystallography, nuclear magnetic resonance, and crystallographic electron microscopy. To determine the percent identity of two amino acid sequences or of two nucleic Alexion Reference: 0693WO acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence).
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide at the corresponding position in the second sequence, then the molecules are identical at that position.
  • the percent identity between the two sequences is a function of the number of identical positions shared by the sequences (e.g., % identity equals [number of identical overlapping positions]/[total number of positions] x 100%). In one embodiment, the two sequences are the same length. [0038] The determination of percent identity between two sequences can be accomplished using a mathematical algorithm known to those of skill in the art.
  • the BLASTn and BLASTx programs Altschul, S.
  • Gapped BLAST can be utilized (Altschul, S.
  • PSI-BLAST can be used to perform an iterated search that detects distant relationships between molecules (Id.).
  • BLAST Gapped BLAST and PSI-BLAST programs
  • the default parameters of the respective programs e.g., BLASTx and BLASTn
  • “Conservative” amino acid substitutions are those substitutions that do not substantially affect or decrease the affinity of a protein, such as an antibody to a target epitope.
  • a monoclonal antibody that immunospecifically binds human light chain amyloid fibril can include at most about 1, at most about 2, at most about 5, at most about 10, or at most about 15 conservative substitutions and immunospecifically bind a human light chain amyloid fibril polypeptide.
  • conservative substitutions also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid, provided that antibody immunospecifically binds the target epitope. Non-conservative substitutions are those that reduce binding to the target epitope.
  • Conservative amino acid substitution tables providing functionally similar amino acids are well known to one of ordinary skill in the art.
  • Alexion Reference 0693WO amino acids that, when amino acids within a group are substituted one for another, can be considered conservative substitutions: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).
  • “Derivative” as used herein refers to a variant polypeptide described herein that comprises, or alternatively consists of, an amino acid sequence of an antibody, which has been altered by the introduction of amino acid residue substitutions, deletions or additions.
  • the term “derivative” as used herein also refers to an antibody that has been modified, e.g., by the covalent attachment of any type of molecule to the polypeptide.
  • an antibody can be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc.
  • a derivative of an antibody or antigen-binding fragment thereof can be modified by chemical modifications using techniques known to those of skill in the art, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc.
  • a derivative of an antibody or antigen-binding fragment thereof may contain one or more non-classical amino acids.
  • a polypeptide derivative possesses a similar or identical function as an antigen-binding fragment thereof, described herein.
  • “Epitopes” as used herein refers to portions of a peptide having antigenic or immunogenic activity in an animal, e.g., a mammal, e.g., a human. Antigenic epitopes need not necessarily be immunogenic.
  • “Fragment” as used herein refers broadly to a polypeptide comprising an amino acid sequence of at least 5 amino acid residues, at least 10 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at least 30 amino acid residues, at least 35 amino acid residues, at least 40 amino acid residues, at least 45 amino acid residues, at least 50 amino acid residues, at least 60 amino residues, at least 70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid residues, at least 100 amino acid residues, at least 125 amino acid residues, at least 150 amino acid residues, at least 175 amino acid residues, at least 200 amino acid residues, or at least 250 amino acid residues, of the amino acid sequence of an antibody (including molecules such as Fabs or scFvs, that comprise, or alternatively consist of, antibody fragments or variants thereof).
  • an antibody including molecules such as Fabs or scFvs, that comprise, or alternatively consist
  • Fusion protein refers broadly to a polypeptide that comprises, or alternatively consists of, an amino acid sequence of an antibody described herein and an amino acid sequence of a heterologous polypeptide (e.g., a polypeptide unrelated to an antibody or antibody domain).
  • High Throughput Fab Antibody Fragment Generation and Ranking allow for generation of antibodies or antibody fragments, e.g., Fab fragments, typically generated by targeted degradation of antibodies- typically through the use of a protease, e.g., papain, pepsin or ficin, from full antibodies and ranking them by binding affinity using label-free biosensing techniques in a high throughput (HT) manner.
  • a protease e.g., papain, pepsin or ficin
  • Ranking antibody variants by their ability to bind to their antigen is a part of the monoclonal antibody drug development process. The antibody ranking procedures are used to differentiate between hits coming out from various antibody discovery efforts, antibody humanization projects, or other projects, to improve lead molecule selection.
  • Described herein are methods that solve both issues at once by: (1) performing all manipulations with a pool of up to 24 antibodies simultaneously using 96-well flat bottom plates and 96-well filter plates (or more, depending on the capacity of the plates), and (2) generating an antibody fragment pool comprising fragments (e.g., Fab fragments) from the antibody pool by, for example, digesting them with papain (or another suitable protease or chemical reaction to generate binding fragments corresponding to the antibody pool) and removing the Fc domain through Protein A purification.
  • the full extent of the digestion and the full extent of Fc removal was confirmed by SDS-PAGE and size exclusion chromatography (SEC) before proceeding to the label-free biosensing-based ranking experiment.
  • Ranking of antibodies by using corresponding fragments (e.g., Fabs) rather than full Igs allows one to eliminate the avidity effect and obtain K off values for a true affinity-based ranking. Using Koff further allows for ranking antibody fragments without having to determine the concentration of the antibody, thereby conferring a significant advantage to rankings based on, for example, K on or K D .
  • Alexion Reference: 0693WO The methods described herein eliminate the avidity effect from a label-free biosensing- based antibody ranking procedure by using, for example, Fab antibody fragments instead of full- length Ig molecules.
  • the high-throughput format allowing one to rapidly rank, depending on the capacity of the plates used in the methods, about 24 antibodies, e.g., in less than one week. Up to 24 antibodies can be ranked in a single experiment by their antigen binding affinity (using Fab antibody fragments) and not avidity (when full Igs are used), using the exemplary system described herein. One of skill in the art would understand that the capacity of the system can be adjusted to rank smaller or larger antibody pools. All 24 Fab fragments were produced under the same conditions, at the same time, which provided an advantage of a direct comparison and ensured a reliable affinity ranking.
  • Label-free Biosensing [0050] Label-free biosensing can be used to determine the antibody fragment binding ranking.
  • Label-free biosensing can be carried out, for example, by: (a) ellipsometry; (b) surface plasmon resonance (SPR); (c) localized SPR using noble metal nanoparticles in solution or on a transparent surface; (d) surface acoustic wave (SAW) devices; (e) quartz-crystal microbalance with dissipation (QCM-D) (e) atomic force microscopy; (f) plasmon-photon coupling; (g) transmission sensing through sub-wavelength nanoholes (enhanced optical transmission); (h) photonic crystal sensing; (i) refraction sensing; (j) guided mode resonance sensing; (k) ring resonator sensing; (l) isothermal titration calorimetry (ITC); (m) microscale thermophoresis; or (n) biolayer interferometry (BLI).
  • SPR surface plasmon resonance
  • QCM-D quartz-crystal microbalance with diss
  • the methods described herein combine preparation of Fab fragments via enzymatic digestion of full-length antibodies (e.g., IgG), isolation of the Fab fragments via Fc fragment removal using Protein A, and high-throughput label-free biosensing, to facilitate the development of antibody drug candidates by quickly screening the Fab fragments.
  • the methods described herein are superior to label-free biosensing-based antibody ranking of full Igs because the instant methods eliminate the avidity component by using Fab antibody fragments instead.
  • Performing plate-based Fab generation with up to, for example, 24 antibodies simultaneously provides a new level of confidence because of actual direct comparison that is indispensable for a reliable affinity ranking.
  • the antibodies described herein can be produced by any method known in the art for the synthesis of antibodies, in particular, for example, by chemical synthesis or by recombinant expression techniques.
  • Single chain Fvs scFvs
  • scFvs Single chain Fvs
  • Antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human or humanized antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described below. Techniques to recombinantly produce Fab, Fab′ and F(ab′)2 fragments can also be employed (WO 92/22324; Mullinax, R. et al., BioTechniques, 12:864-9, 1992; Sawai, H. et al., Am. J. Reprod. Immunol., 34:26-34, 1995; Better, M. et al., Science, 240:1041-3, 1988).
  • PCR primers including VH or VL nucleotide sequences, a restriction site, and a flanking sequence to protect the restriction site can be used to amplify the VH or VL sequences in scFv clones.
  • VH constant region e.g., the human gamma 4 constant region
  • VL constant region e.g., human kappa or lambda constant regions.
  • Vectors for expressing the VH or VL domains can comprise a promoter suitable to direct expression of the heavy and light chains in the chosen expression system, a secretion signal, a cloning site for the Ig variable domain, Ig constant domains, and a selection marker such as neomycin.
  • the VH and VL domains may also be cloned into one vector expressing the necessary constant regions.
  • the heavy chain conversion vectors and light chain conversion vectors are then co-transfected into cell lines to generate stable or transient cell lines that express full-length antibodies, e.g., lgG, using techniques known to those of skill in the art.
  • an antibody described herein including molecules comprising, or alternatively consisting of, antibody fragments, or variants thereof
  • it can be purified by any method known in the art for purification of Alexion Reference: 0693WO an immunoglobulin molecule, or more generally, a protein molecule, such as, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • humanized antibodies described herein can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification. Identified antibody fragments can be engineered back into fill-length antibodies or other engineered binding molecules based on identified CDRs.
  • Host cells used to express the antibodies can be either a bacterial cell such as E.coli, yeast (e.g., S. cerevisiae), or a eukaryotic cell (e.g., a mammalian cell line).
  • a mammalian cell of a well-defined type for this purpose such as a myeloma cell, 3T3, HeLa, C6A2780, Vero, MOCK II, a Chinese hamster ovary (CHO), Sf9, Sf21, COS, NS0, or HEK293 cell line can be used.
  • the general methods for constructing vectors, the transfection methods required to produce the host cell, and the culturing methods required to produce the antibodies and fragments thereof from said host cells include conventional techniques.
  • the cell line used to produce antibodies is preferably a mammalian cell line, any other suitable cell line, such as a bacterial cell line such as an E.
  • the binding specificity of antibodies can be determined by any suitable means. Examples of suitable assays to measure binding specificity include, but are not limited to, immunoprecipitation or in vitro binding assays, such as radioimmunoassay (RIA) or enzyme- linked immunoadsorbent assay (ELISA). Other means, such as, for example, SPR or any techniques described above or that become known may also be used. [0059] The binding affinity of antibodies can, for example, be determined for example, by Scatchard analysis (Frankel, M. & Gerhard, W., Mol. Immunol., 16:101-6, 1979).
  • binding affinity is measured by an antigen/antibody dissociation rate.
  • High binding affinity can be measured by a competition radioimmunoassay.
  • Binding affinity can be measured by ELISA.
  • Antibody affinity can be measured by flow cytometry.
  • An antibody that “specifically binds” or “immunospecifically binds” an antigen is an antibody that binds the antigen with high affinity and does not significantly bind other unrelated antigens.
  • the antibodies can bind an epitope with a binding affinity from picomolar range (very high affinity) to low micromolar range (weak binders).
  • Most antibody drugs have a dissociation Alexion Reference: 0693WO constant (Kd) in low nanomolar to picomolar range, e.g., about 1 pM, about 900 nM, about 80 pM, about 700 nM, about 200 pM, about 500 nM, about 500 pM, about 400 nM, about 750 pM, about 900 nM, about 500 pM, about 900 nM, about 100 pM, about 900 nM, about 50 pM or about 500 nM.
  • Kd dissociation Alexion Reference: 0693WO constant
  • the antibodies described herein may be “chimeric,” which refers to an antibody in which a portion of the heavy chain or light chain is derived from a particular source or species, while at least a part of the remainder of the heavy chain or light chain is derived from a different source or species.
  • a chimeric antibody refers to an antibody comprising at least one variable region from a first species (such as mouse, rat, cynomolgus monkey, etc.) and at least one constant region from a second species (such as human, dog, cat, equine, etc.).
  • a “humanized antibody” means an antibody in which at least one amino acid in a portion of a non-human variable region has been replaced with the corresponding amino acid from a human variable region.
  • a humanized antibody comprises at least one human constant region (e.g., a ⁇ constant region, an ⁇ constant region, a ⁇ constant region, an ⁇ constant region, a ⁇ constant region, or etc.) or fragment thereof.
  • a humanized antibody is an antibody fragment, such as Fab, scFv, (Fab’)2, etc.
  • humanized also denotes forms of non-human (for example, murine) antibodies that are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab’, F(ab’)2 or other antigen- binding sequences of antibodies) that contain minimal sequence of non-human immunoglobulin.
  • Humanized antibodies can include human immunoglobulins (recipient antibody) in which residues from a CDR of the recipient are substituted by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity.
  • donor antibody such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity.
  • Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • the humanized antibody can comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences, but are included to further refine and optimize antibody performance.
  • Monoclonal antibodies [0062]
  • the monoclonal antibodies disclosed herein can be of any isotype.
  • the monoclonal antibody can be, for example, an IgM or an IgG antibody, such as IgG1 or an IgG2.
  • the class of an antibody can be switched with another (for example, IgG can be switched to IgM), according Alexion Reference: 0693WO to known procedures. Class switching can also be used to convert one IgG subclass to another, such as from IgG1 to IgG2.
  • the humanized antibodies described herein can be monovalent, bivalent, trivalent or multivalent.
  • monovalent scFvs can be multimerized either chemically or by association with another protein or substance.
  • An scFv that is fused to a hexahistidine tag or a Flag tag can be multimerized using Ni-NTA agarose (Qiagen) or using anti-Flag antibodies (Stratagene, Inc.).
  • Humanized antibodies can be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies can be specific for different epitopes or a heterologous epitope, such as a heterologous polypeptide or solid support material.
  • a full-length antibody pool was obtained and digested by papain to produce Fc and Fab fragments according to the following protocol: (1) Prepared fresh digestion buffer: 20 mM sodium phosphate, 10 mM EDTA, 20 mM Cysteine-HCl, adjust to pH 7.0; (2) Prepared washed papain resin: wash 500 ⁇ L of papain resin (Fisher Scientific, cat #20341) in 4 mL of digestion buffer twice, resuspend in 500 ⁇ L digestion buffer; (3) Prepared antibody samples by adding 50 ⁇ L of 1 mg/mL antibody to 50 ⁇ L of digestion buffer, and transferred to a 96-well plate; (4) Added 50 ⁇ L of washed papain resin to 100 ⁇ L antibody samples on the plate.
  • the Fab fragments were purified using Protein A, as described below: (1) Prepared binding buffer: 20 mM sodium phosphate, pH 7.4; (2) Washed 500 ⁇ L of Protein A resin (Fisher Scientific, cat#15918014) in 4 mL of binding buffer twice, and resuspend in 500 ⁇ L binding buffer; (3) Added 100 ⁇ L of the Fc and Fab fragments generated by papain digestion, as described above, to a 96-well plate; (4) Added 50 ⁇ L of Protein A resin (Fisher Scientific, cat#15918014) to each 100 ⁇ L of IgG fragments.
  • Protein A as described below: (1) Prepared binding buffer: 20 mM sodium phosphate, pH 7.4; (2) Washed 500 ⁇ L of Protein A resin (Fisher Scientific, cat#15918014) in 4 mL of binding buffer twice, and resuspend in 500 ⁇ L binding buffer; (3) Added 100 ⁇ L of the Fc and Fab fragments generated by papain digestion, as described above,
  • Fab fragments were produced and purified, as described above, they were ranked by antigen binding using a high-throughput biolayer interference (BLI) system, comprising: (1) Used biotinylated antigen and Streptavidin biosensors Octet (Fortebio cat#18-5019); (2) Performed BLI scouting experiments to determine optimal biotinylated antigen and Fab fragments concentration to use; (3) Ran BLI kinetics experiment on a high throughput BLI instrument (Octet HTX system); and (4) Analyzed data to determine Koff values for each Fab fragment and rank binders accordingly.
  • BLI biolayer interference

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des méthodes et des dosages destinés au classement à haut débit de liaison à l'antigène par génération et test de fragments d'anticorps à partir d'anticorps pleine longueur.
PCT/US2024/027448 2023-05-04 2024-05-02 Génération et classement de fragments d'anticorps fab à haut débit Pending WO2024229245A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363463995P 2023-05-04 2023-05-04
US63/463,995 2023-05-04

Publications (3)

Publication Number Publication Date
WO2024229245A2 WO2024229245A2 (fr) 2024-11-07
WO2024229245A9 true WO2024229245A9 (fr) 2024-12-26
WO2024229245A3 WO2024229245A3 (fr) 2025-02-06

Family

ID=93333493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/027448 Pending WO2024229245A2 (fr) 2023-05-04 2024-05-02 Génération et classement de fragments d'anticorps fab à haut débit

Country Status (1)

Country Link
WO (1) WO2024229245A2 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3045182T3 (en) * 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT

Also Published As

Publication number Publication date
WO2024229245A3 (fr) 2025-02-06
WO2024229245A2 (fr) 2024-11-07

Similar Documents

Publication Publication Date Title
EP2871189A1 (fr) Anticorps TAG anti Strep monoclonaux à affinité élevée
US10604586B2 (en) Humanized monoclonal antibody and uses thereof
CN108026180B (zh) 抗羟腐胺赖氨酸抗体及其用途
EP3650547A1 (fr) Anticorps monoclonal anti-igg4 humaine et réactif de dosage d'igg4 humaine l'utilisant
JP2025503573A (ja) 抗ｇｐｒｃ５ｄ抗体及びその応用
EP3533459A1 (fr) Anticorps anti-pla2-gib et leurs utilisations
US20140243265A1 (en) Antibodies to modified human igf-1/e peptides
CN116925230A (zh) 一种抗人pla2r的抗体及其抗原结合片段及其应用
CN116554323B (zh) 人源化抗il21抗体的开发和应用
CN109336973B (zh) 抗转铁蛋白抗体及其用途
WO2024229245A2 (fr) Génération et classement de fragments d'anticorps fab à haut débit
CN120225680A (zh) 针对外被体蛋白复合物亚基β2的抗体
WO2022078466A1 (fr) Procédés d'atténuation de l'interférence par des anticorps anti-cd47 thérapeutiques dans des dosages de pré-transfusion
EP4441100A1 (fr) Anticorps à domaine unique bloquant et non bloquants et leurs utilisations
CN119735680B (zh) 一种抗cd28的单克隆抗体及细胞
CN110794144A (zh) 用于检测诱导性免疫共刺激分子的试剂盒及其用途
EP4549462A1 (fr) Anticorps spécifique de propeptide n-terminal de procollagène, kit et utilisation associée
CN119874904B (zh) 抗NT-proBNP抗体及其用途
CN110579610A (zh) 用于检测t细胞活化的v域免疫抑制因子的试剂盒
WO2025061149A1 (fr) Anticorps anti-gcc, récepteur antigénique chimérique et utilisation
WO2025249551A1 (fr) Méthode permettant de quantifier le mésappariement de l'échange de chaînes légères d'un anticorps bispécifique
JP2020530901A (ja) ミニブタ試料において抗薬物抗体を決定するための方法
EP4268847A1 (fr) Composition pharmaceutique pour le traitement de la sclérose latérale amyotrophique
JP7107497B2 (ja) Ｄｎａ鎖上のアデノシン型サイクロプリンに特異的に結合する抗体
JP2023513282A (ja) 抗ｃｄ１９キメラ抗原受容体を標的とする抗イディオタイプ抗体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24800595

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024800595

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2024800595

Country of ref document: EP

Effective date: 20251204

ENP Entry into the national phase

Ref document number: 2024800595

Country of ref document: EP

Effective date: 20251204

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24800595

Country of ref document: EP

Kind code of ref document: A2